Quantum Genomics, a biopharmaceutical research company developing new treatments in the field of cardiovascular diseases, has announced a capital increase gained through private placements totalling €3.4 million through the issuance of 637,334 new shares at a unit price of €5.35.
Following this transaction, Quantum Genomics has announced both the transfer and the resumption of trading of its securities on the Alternext market of Euronext Paris from 10 April, 2014. These securities will be listed continuously and a liquidity agreement is being drawn up with Aurel BGC. The ISIN code remains unchanged (FR0011648971) whereas the ticker symbol will become ALQGC from said date.
